This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US
by Zacks Equity Research
QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod
by Zacks Equity Research
Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.
ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.
Medtronic's (MDT) Evolut TAVR Label Expansion Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) Low Risk Bicuspid Study shows bicuspid patients implanted with Evolut TAVR had low rates (1.3%) of all-cause mortality.
TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle
by Zacks Equity Research
The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Medtronic Initiates Post-Market ELITE Study for SNM Therapy
by Zacks Equity Research
Medtronic's (MDT) ELITE study is expected to reinforce long-term safety, efficacy and patient benefit from the SNM therapy.
MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential
by Urmimala Biswas
MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.
Albireo (ALBO) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Medtronic Publishes IN.PACT AV Access Trial Study Results
by Zacks Equity Research
Medtronic's (MDT) IN.PACT AV demonstrates significant reductions in hospital visits for AV fistulae maintenance, which is leading to successful and uninterrupted dialysis of ESRD patients.
Globus Medical Sees Strong Rebound Despite Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.
7 Top-Ranked Corporate Giants With More Than 50% Return YTD
by Nalak Das
A handful of corporate giants (market capital > $10 billion) have skyrocketed this year, braving the pandemic and its impact on businesses.
QIAGEN Launches Primer Panel for NGS of Coronavirus Genome
by Zacks Equity Research
QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.
Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking
by Zacks Equity Research
Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.
Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?
by Urmimala Biswas
The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.
Boston Scientific's Voraxaze's MAA Accepted by EMA for Review
by Zacks Equity Research
Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
EPA Validates NEOGEN's Disinfectant for Use Against COVID-19
by Zacks Equity Research
NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.
Omnicell, Pharmaceutical Strategies Enter Acquisition Deal
by Zacks Equity Research
Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.
Medtronic (MDT) Plans $160 Million R&D Investment in India
by Zacks Equity Research
The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.
Medtronic Plans New Acquisition in AI-Driven Diabetes Care
by Zacks Equity Research
Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.
QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.